Whole-body Magnetic Resonance Imaging Provides Accurate Staging of Diffuse Large B-cell Lymphoma, but is Less Preferred by Patients

Overview

Journal World J Radiol

Publisher Baishideng Publishing Group

Date 2025 Jan 29

PMID 39876887

Authors

Lukas Lambert

Monika Wagnerova

Prokop Vodicka

Katerina Benesova

David Zogala

Marek Trneny

Andrea Burgetova

Affiliations

Soon will be listed here.

Abstract

Background: Whole-body magnetic resonance imaging (wbMRI) allows general assessment of systemic cancers including lymphomas without radiation burden.

Aim: To evaluate the diagnostic performance of wbMRI in the staging of diffuse large B-cell lymphoma (DLBCL), determine the value of individual MRI sequences, and assess patients' concerns with wbMRI.

Methods: In this single-center prospective study, adult patients newly diagnosed with systemic DLBCL underwent wbMRI on a 3T scanner [diffusion weighted images with background suppression (DWIBS), T2, short tau inversion recovery (STIR), contrast-enhanced T1] and fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) (reference standard). The involvement of 12 nodal regions and extranodal sites was evaluated on wbMRI and PET/CT. The utility of wbMRI sequences was rated on a five-point scale (0 = not useful, 4 = very useful). Patients received a questionnaire regarding wbMRI.

Results: Of 60 eligible patients, 14 (23%) were enrolled and completed the study. The sensitivity of wbMRI in the nodal involvement (182 nodal sites) was 0.84, with 0.99 specificity, positive predictive value of 0.96, negative predictive value of 0.97, and 0.97 accuracy. PET/CT and wbMRI were concordant both in extranodal involvement (13 instances) and staging (κ = 1.0). The mean scores of the utility of MRI sequences were 3.71 ± 0.73 for DWIBS, 2.64 ± 0.84 for T1, 2.14 ± 0.77 for STIR, and 1.29 ± 0.73 for T2 ( < 0.0001). Patients were mostly concerned about the enclosed environment and duration of the MRI examination (27% of patients).

Conclusion: The wbMRI exhibited excellent sensitivity and specificity in staging DLBCL. DWIBS and contrast-enhanced T1 were rated as the most useful sequences. Patients were less willing to undergo wbMRI as a second examination parallel to PET/CT, especially owing to the long duration and the enclosed environment.

References

Hofman M, Smeeton N, Rankin S, Nunan T, ODoherty M . Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging. J Nucl Med. 2009; 50(10):1594-7. DOI: 10.2967/jnumed.109.064121. View

Yoo K . Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT. Blood Res. 2022; 57(S1):75-78. PMC: 9057662. DOI: 10.5045/br.2022.2022055. View

Madl J, Nieto Alvarez I, Amft O, Rohleder N, Becker L . The Psychological, Physiological, and Behavioral Responses of Patients to Magnetic Resonance Imaging (MRI): A Systematic Review and Meta-Analysis. J Magn Reson Imaging. 2023; 59(2):675-687. DOI: 10.1002/jmri.29134. View

Coiffier B, Thieblemont C, Van den Neste E, Lepeu G, Plantier I, Castaigne S . Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116(12):2040-5. PMC: 2951853. DOI: 10.1182/blood-2010-03-276246. View

Davies A, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G . Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. J Clin Oncol. 2023; 41(15):2718-2723. PMC: 10414744. DOI: 10.1200/JCO.23.00033. View

Tilly H, Morschhauser F, Sehn L, Friedberg J, Trneny M, Sharman J . Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021; 386(4):351-363. PMC: 11702892. DOI: 10.1056/NEJMoa2115304. View

Aamir F, Aslam I, Arshad M, Omer H . Accelerated Diffusion-Weighted MR Image Reconstruction Using Deep Neural Networks. J Digit Imaging. 2022; 36(1):276-288. PMC: 9984585. DOI: 10.1007/s10278-022-00709-5. View

Kaalep A, Sera T, Oyen W, Krause B, Chiti A, Liu Y . EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems. Eur J Nucl Med Mol Imaging. 2017; 45(3):412-422. PMC: 5787222. DOI: 10.1007/s00259-017-3853-7. View

Madl J, Janka R, Bay S, Rohleder N . MRI as a Stressor: The Psychological and Physiological Response of Patients to MRI, Influencing Factors, and Consequences. J Am Coll Radiol. 2022; 19(3):423-432. DOI: 10.1016/j.jacr.2021.11.020. View

10.

Fischerova D, Pinto P, Burgetova A, Masek M, Slama J, Kocian R . Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study). Ultrasound Obstet Gynecol. 2021; 59(2):248-262. DOI: 10.1002/uog.23654. View

11.

Husby T, Johansen H, Bogsrud T, Hustad K, Evensen B, Boellard R . A comparison of FDG PET/MR and PET/CT for staging, response assessment, and prognostic imaging biomarkers in lymphoma. Ann Hematol. 2022; 101(5):1077-1088. PMC: 8993743. DOI: 10.1007/s00277-022-04789-9. View

12.

Littooij A, Kwee T, de Keizer B, Bruin M, Coma A, Beek F . Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study. J Magn Reson Imaging. 2015; 42(6):1646-55. DOI: 10.1002/jmri.24938. View

13.

Abdulqadhr G, Molin D, Astrom G, Suurkula M, Johansson L, Hagberg H . Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol. 2011; 52(2):173-80. DOI: 10.1258/ar.2010.100246. View

14.

Vitolo U, Trneny M, Belada D, Burke J, Carella A, Chua N . Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017; 35(31):3529-3537. DOI: 10.1200/JCO.2017.73.3402. View

15.

Taylor S, Mallett S, Beare S, Bhatnagar G, Blunt D, Boavida P . Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. Lancet Gastroenterol Hepatol. 2019; 4(7):529-537. PMC: 6547166. DOI: 10.1016/S2468-1253(19)30056-1. View

16.

Kostakoglu L, Martelli M, Sehn L, Belada D, Carella A, Chua N . End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021; 5(5):1283-1290. PMC: 7948296. DOI: 10.1182/bloodadvances.2020002690. View

17.

El-Galaly T, Gormsen L, Hutchings M . PET/CT for Staging; Past, Present, and Future. Semin Nucl Med. 2017; 48(1):4-16. DOI: 10.1053/j.semnuclmed.2017.09.001. View

18.

Lambert L, Burgetova A, Trneny M, Bircakova B, Molinsky J, Benesova K . The diagnostic performance of whole-body MRI in the staging of lymphomas in adult patients compared to PET/CT and enhanced reference standard-systematic review and meta-analysis. Quant Imaging Med Surg. 2022; 12(2):1558-1570. PMC: 8739096. DOI: 10.21037/qims-21-649. View

19.

Hagtvedt T, Seierstad T, Lund K, Londalen A, Bogsrud T, Smith H . Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma. Acta Radiol. 2014; 56(2):152-8. DOI: 10.1177/0284185114526087. View

20.

Jurka M, Macova I, Wagnerova M, Capoun O, Jakubicek R, Ourednicek P . Deep-learning-based reconstruction of T2-weighted magnetic resonance imaging of the prostate accelerated by compressed sensing provides improved image quality at half the acquisition time. Quant Imaging Med Surg. 2024; 14(5):3534-3543. PMC: 11074762. DOI: 10.21037/qims-23-1488. View